



Financial Tear Sheet

Where the power of nature meets the logic of science for the betterment of health.

ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting. As a result of our relationships with leading universities and research institutions, we are able to discover and acquire early stage, ingredient technologies that are protected by intellectual property. We then utilize our in-house chemistry, regulatory and safety consulting business units to commercialize the ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive patent protection. Our portfolio of ingredient technologies includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene and; PUREENERGY®, a caffeine-pTeroPure® co-crystal. To learn more about ChromaDex, please visit www.chromadex.com.

ChromaDex Contact:

Andrew Johnson, Director of Investor Relations

949-419-0288

andrewj@chromadex.com

Stock Performance

CDXC (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$3.70
Change (%)	▼ 0.12 (3.14%)
Volume	325,314
52 Week Low	\$2.25
Market Cap	\$170,547,408
Rolling EPS	-0.14
PE Ratio	N/A
Shares Outstanding	46,093,894

Data as of 06/28/17 4:00 p.m. ET



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Headlines & Events

Date	Title
06/27/17	ChromaDex Appoints Harvard Medical School Professor of Neurology, Dr. Rudolph Tanzi, to the Scientific Advisory Board
06/12/17	ChromaDex announces an exclusive worldwide patent license and research agreement with The Scripps Research Institute to identify the potential role of NIAGEN® in treating breast cancer
06/05/17	ChromaDex Names World's Leading Expert on Nicotinamide Riboside and NAD as Chief Scientific Advisor

There are currently no events scheduled.

SEC Filings

Filing Date	Form
06/23/17	8-K
06/21/17	EFFECT
06/21/17	424B3
06/20/17	DEFA14A

Corporate Governance

Frank L. Jaksch Jr.	CEO
Steve R. Allen	Chairman
Jeff Baxter	Non-Executive Director
Steven A. Block	Non-Executive Director
Rob Fried	President and Chief Strategy Officer
Kurt Gustafson	Non-Executive Director
Steven D. Rubin	Non-Executive Director

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	82	79.60	54.9	25,307,084
Mutual Fund	80	7.72	5.4	2,506,307
Insider *	5	5.48	3.1	1,429,798

*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
Champion River Ventures, Ltd.	4,589,980	10.0	4,589,980	05/26/17
Frost Phillip MD ET AL	3,469,521	7.5	-414,500	09/12/16
Pioneer Step Holdings, Ltd.	3,059,988	6.6	3,059,988	05/26/17
Brauser (Michael H)	2,933,220	6.4	3	05/25/17
Honig (Barry Charles)	2,409,312	5.2	-488,299	12/31/16
Black Sheep, FLP	2,075,052	4.5	0	05/25/17
BlackRock Institutional Trust Company, N.A.	1,095,181	2.4	-1,439	03/31/17
The Vanguard Group, Inc.	985,272	2.1	39,052	03/31/17
Tieton Capital Management, LLC	688,735	1.5	688,735	03/31/17
Smithburg (William D)	640,000	1.4	640,000	06/06/16